BriaCell Therapeutics Corp. (BCTX): R&D Expense

Annual figures by period end, from SEC filings.

$29.24M
Year ended 2026-07-31
+24.0%
3-year compound annual growth
+70.6%
5-year compound annual growth
2021-07-31: $2.02M2022-07-31: $8.02M2023-07-31: $15.34M2024-07-31: $27.18M2025-07-31: $21.27M2026-07-31: $29.24M$29.24M
2021-07-31 R&D Expense (USD) 2026-07-31
Period endedR&D ExpenseChange YoYSource filing
2026-07-31$29.24M+37.4%2026-10-28, From 2025-08-01
2025-07-31$21.27M-21.7%2026-10-28, From 2024-08-01
2024-07-31$27.18M+77.2%2025-10-16, From 2023-08-01
2023-07-31$15.34M+91.2%2024-10-29, From 2022-08-01
2022-07-31$8.02M+296.9%2023-10-25, From 2021-08-01
2021-07-31$2.02Mn/a2022-10-28, From 2020-08-01

R&D Expense at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
BriaCell Therapeutics Corp. (BCTX)2026-07-31$29.24M+37.4%
Immunic, Inc. (IMUX)2025-12-31$81.98M+2.4%
Rein Therapeutics, Inc. (RNTX)2025-12-31$11.03M-22.6%
Kiora Pharmaceuticals Inc (KPRX)2025-12-31$10.78M+37.5%
CervoMed Inc. (CRVO)2025-12-31$21.82M+16.1%
Gain Therapeutics, Inc. (GANX)2025-12-31$10.21M-5.4%
HCW Biologics Inc. (HCWB)2025-12-31$5.44M-14.8%
Moleculin Biotech, Inc. (MBRX)2025-12-31$15.89M-10.4%
CASI Pharmaceuticals, Inc. (CASIF)2025-12-31$6.31M-29.3%

Compare BCTX, IMUX, RNTX, KPRX side by side · Screen every company in Pharmaceutical Preparations ↗